Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling

Juan Xiao, Manman Xu, Teng Hou, Yongwen Huang, Chenlu Yang, Jundong LiMolecular 2015 · DOI

Abstract

Src family tyrosine kinase (SFK) activation is closely associated with the progression of ovarian cancer, making SFKs a primary target for therapeutic intervention. This study investigated the antitumor activity of dasatinib, a tyrosine kinase inhibitor, both as a monotherapy and in combination with paclitaxel. High levels of phosphorylated Src (p-Src) were observed across six ovarian cancer cell lines, indicating active Src signaling. Crucially, paclitaxel treatment was found to further increase p-Src expression, suggesting a potential survival mechanism triggered by chemotherapy. Dasatinib treatment effectively downregulated p-Src and induced apoptosis. When combined, dasatinib and paclitaxel demonstrated significant synergy in vitro and potent tumor growth inhibition in vivo, with inhibitory rates reaching up to 76.7% in murine xenograft models.

Introduction

Ovarian cancer remains a significant clinical challenge, primarily due to high relapse rates and the development of resistance to standard platinum- and taxane-based chemotherapies. Approximately 75% of patients eventually face chemoresistance, necessitating the search for targeted therapies that can enhance the efficacy of traditional treatments. Src family kinases (SFKs) are known to drive tumor progression, survival, and metastasis. While dasatinib is FDA-approved for certain leukemias, its potential to sensitize ovarian cancer to paclitaxel required further investigation. This study explores whether dasatinib can overcome resistance by targeting the Src signaling pathway.

Materials and Methods

The researchers utilized six human ovarian cancer cell lines: A2780, HO8910, OVCAR3, CAOV3, COC1, and SKOV3.

  • Molecular Analysis: Western blotting was employed to measure the expression of Src and its active form, p-Src-Y416.
  • Cellular Assays: MTT assays were used to evaluate cell viability, while Annexin V-fluorescein isothiocyanate staining measured apoptosis rates.
  • Synergy Quantification: The Combination Index (CI) was calculated using Calcusyn software to determine if drug interactions were synergistic (CI < 1).
  • In Vivo Modeling: BALB/c nude mice were used to establish xenografts of A2780 and HO8910 cells to assess tumor volume and weight over a 31-day treatment period.

Results

The "Paclitaxel Paradox": Src Activation

A key finding of this study was that paclitaxel treatment, while intended to kill cancer cells, actually increased the levels of active p-Src. This "Paclitaxel Paradox" suggests that the chemotherapy itself may inadvertently trigger a survival pathway in the cancer cells, potentially contributing to drug resistance.

Paclitaxel treatment increases p-Src expression in a dose- and time-dependent manner in A2780 cells.

Dasatinib as a Potent Growth Inhibitor

Dasatinib monotherapy demonstrated clear anti-ovarian cancer properties. It inhibited cell growth in a dose-dependent manner across the tested lines, with IC50 values of 7.30 µM for A2780 and 2.51 µM for HO8910 cells.

Dose-dependent inhibition of cell viability by dasatinib in A2780 and HO8910 ovarian cancer cell lines.

Synergistic Effects and In Vivo Efficacy

When combined, dasatinib effectively neutralized the paclitaxel-induced Src activation. This combination led to significantly higher rates of apoptosis compared to either drug alone. For instance, in HO8910 cells, the combination treatment increased the apoptosis rate to 43.6%, compared to 22.0% for paclitaxel alone.

In mouse models, the synergy was even more pronounced. The combination therapy achieved a Tumor Growth Inhibitory (TIR) rate of 76.7% for A2780 tumors and 58.5% for HO8910 tumors. Importantly, the treatment was well-tolerated, with no significant weight loss or acute toxicity observed in the subjects.

Discussion and Conclusion

This study highlights the critical role of the Src signaling pathway in ovarian cancer's response to chemotherapy. By demonstrating that paclitaxel activates Src and that dasatinib can effectively block this activation, the researchers have identified a clear molecular mechanism for synergy. The combination of dasatinib and paclitaxel not only inhibits proliferation but also actively promotes programmed cell death more effectively than standard care. These findings suggest that Src inhibition could be a viable clinical strategy to enhance the efficacy of paclitaxel and overcome chemoresistance in ovarian cancer patients.

Summary updated

Abstract

Src family tyrosine kinase (SFK) activation is associated with ovarian cancer progression. Therefore, SFKs are targets for the development of potential treatments of ovarian cancer. Dasatinib is a tyrosine kinase inhibitor that targets SFK activity, and is used for the treatment of B cell and Abelson lymphomas. At the present time, the potential effect of dasatinib on ovarian cancer is not clear. The aim of the present study was to investigate the antitumor activity of dasatinib, alone and in combination with paclitaxel, in ovarian cancer in vitro and in vivo. In the present study, the expression of Src and phospho‑Src-Y416 (p‑Src) was measured in six ovarian cancer cell lines using western blotting and immunohistochemistry. In addition, cell viability and apoptosis were measured using an MTT assay and annexin V‑fluorescein isothiocyanate staining. An ovarian cancer murine xenograft model was established, in order to evaluate the antitumor effect of dasatinib alone and in combination with paclitaxel in ovarian cancer. High levels of p‑Src protein expression were observed in all cell lines, as compared with healthy cells, which indicated activation of the Src signaling pathway. p‑Src expression increased in ovarian cancer cells following paclitaxel treatment. Dasatinib treatment demonstrated anti‑ovarian cancer properties, by downregulating p‑Src expression and by inducing cancer cell apoptosis. Combined treatment with dasatinib and paclitaxel markedly inhibited proliferation and promoted apoptosis of ovarian cancer cells, compared with control cells. Combined dasatinib and paclitaxel treatment exhibited antitumor activities in vivo and in vitro (combination indices, 0.25‑0.93 and 0.31‑0.75; and tumor growth inhibitory rates, 76.7% and 58.5%, in A2780 and HO8910 cell lines, respectively), compared with paclitaxel treatment alone. Dasatinib monotherapy demonstrated anti‑ovarian cancer activities. The effects of dasatinib and paclitaxel treatments on ovarian cancer cells appeared to be mediated by the Src pathway.
BibTeX
@inproceedings{xiao2015dasatinib,
  author = {Juan Xiao and Manman Xu and Teng Hou and Yongwen Huang and Chenlu Yang and Jundong Li},
  title = {{Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling}},
  booktitle = {Molecular},
  year = {2015},
  doi = {10.3892/mmr.2015.3784},
}
Figure